Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
445.52
-1.31 (-0.29%)
Jun 8, 2026, 12:22 PM EDT - Market open
Vertex Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12,218 | 12,001 | 11,020 | 9,869 | 8,931 | 7,574 | |
Revenue Growth (YoY) | 10.08% | 8.90% | 11.66% | 10.51% | 17.91% | 22.06% |
Cost of Revenue | 1,681 | 1,651 | 1,531 | 1,262 | 1,080 | 904.2 |
Gross Profit | 10,537 | 10,350 | 9,490 | 8,607 | 7,850 | 6,670 |
Selling, General & Admin | 1,850 | 1,753 | 1,464 | 1,137 | 944.7 | 840.1 |
Research & Development | 4,005 | 4,043 | 8,259 | 3,690 | 2,656 | 3,051 |
Other Operating Expenses | 0.1 | 381.1 | -0.5 | -51.6 | -57.5 | -3.1 |
Total Operating Expenses | 5,856 | 6,177 | 9,723 | 4,775 | 3,543 | 3,888 |
Operating Income | 4,681 | 4,173 | -232.9 | 3,832 | 4,307 | 2,782 |
Interest Income | 370 | 490.9 | 598.1 | 614.7 | 144.6 | 4.9 |
Interest Expense | -10.3 | -13.3 | -30.6 | -44.1 | -54.8 | -61.5 |
Other Non-Operating Income (Expense) | 124.7 | -7.7 | -86.1 | -22.8 | -164.8 | 4.9 |
Total Non-Operating Income (Expense) | 484.4 | 469.9 | 481.4 | 547.8 | -75 | -51.7 |
Pretax Income | 5,166 | 4,643 | 248.5 | 4,380 | 4,232 | 2,730 |
Provision for Income Taxes | 827.4 | 690 | 784.1 | 760.2 | 910.4 | 388.3 |
Net Income | 4,338 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Net Income to Common | 3,305 | 3,953 | -535.6 | 3,620 | 3,322 | 2,342 |
Net Income Growth | 26.90% | - | - | 8.96% | 41.84% | -13.63% |
Shares Outstanding (Basic) | 255 | 256 | 258 | 258 | 256 | 258 |
Shares Outstanding (Diluted) | 257 | 258 | 258 | 261 | 259 | 260 |
Shares Change (YoY) | -0.98% | 0.04% | -1.00% | 0.54% | -0.31% | -1.33% |
EPS (Basic) | 17.01 | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 |
EPS (Diluted) | 16.86 | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 |
EPS Growth | - | - | - | 8.35% | 42.29% | -12.44% |
Shares Outstanding | 254.16 | 253.99 | 256.9 | 257.7 | 257.01 | 254.48 |
Free Cash Flow | 3,710 | 3,194 | -790.3 | 3,337 | 3,925 | 2,409 |
Free Cash Flow Growth | 16.17% | - | - | -14.99% | 62.97% | -19.55% |
Free Cash Flow Per Share | 14.42 | 12.38 | -3.06 | 12.81 | 15.15 | 9.27 |
Gross Margin | 86.24% | 86.24% | 86.11% | 87.21% | 87.90% | 88.06% |
Operating Margin | 38.31% | 34.77% | -2.11% | 38.83% | 48.23% | 36.73% |
Profit Margin | 35.51% | 32.94% | -4.86% | 36.68% | 37.20% | 30.92% |
FCF Margin | 30.37% | 26.61% | -7.17% | 33.81% | 43.95% | 31.80% |
EBITDA | 4,899 | 4,383 | -25.7 | 4,013 | 4,456 | 2,908 |
EBITDA Margin | 40.09% | 36.52% | -0.23% | 40.66% | 49.89% | 38.39% |
EBIT | 4,681 | 4,173 | -232.9 | 3,832 | 4,307 | 2,782 |
EBIT Margin | 38.31% | 34.77% | -2.11% | 38.83% | 48.23% | 36.73% |
Effective Tax Rate | 16.02% | 14.86% | 315.53% | 17.36% | 21.51% | 14.22% |